NEW YORK (GenomeWeb News) – Dako announced late on Monday that the US Food and Drug Administration has approved its HercepTest and HER2 FISH pharmDx as companion diagnostics for Genentech's breast cancer drug Perjeta (pertuzumab).

FDA also approved the drug.

Dako's assays will be used to identify patients with HER2-positive metastatic breast cancer who may be eligible for treatment with Perjeta and are available immediately.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.